Top of this page
Skip navigation, go straight to the content

Investors ESG overview

Our work has an impact on the lives of many people.


Every UCB employee is committed to follow the strict regulatory standards for research, development, manufacturing and distribution of our products to ensure we meet all safety, quality, regulatory, legal and environmental requirements.




All our activities have an impact on the environment. At UCB, we take our responsibility to the planet very seriously. 

We commit to reducing our ecological footprint  with the thinking that it does not make sense to provide our patients with solutions for their diseases, on the one hand, while on the other, destroying  the environment they live in. 

For the past 10 years, we have made progress in this direction by improving our buildings and processes, raising awareness and encouraging greener behaviors.

 UCB set ambitious targets to be reached by 2030:

Become carbon neutral :

  • reducing the emissions by 35% 
  • compensating those we cannot reduce

Reduce water consumption by 20%


Reduce waste generation by 25%


In 2019, we further strengthened our commitment to reduce our GHG emissions by submitting our environmental targets to the Science Based Target Initiative and further extended our impact across our network of partners and our value chain.

These activities contributed to the progress made since we implemented our green goals in 2016, with a 31% reduction in our energy consumption, 27% reduction in our water consumption, 32% in our waste production.

As all targets set are absolute, the expected growth of UCB’s operations in the coming years will nevertheless require continued efforts to meet our 2030 targets.


Curious to know more?

Find out how UCB is minimizing its environmental footprint in the 2019 annual integrated report.



Our ability to make a significant difference to the lives of people living with severe diseases
depends on the talent and commitment of our people.

Each team member brings expertise in a specific aspect of drug development
such as manufacturing, commercialization, safety, quality, regulatory affairs or medical compliance. 

image description

In today’s very complex environment, the power of collaboration, engagement and an open and transparent dialogue are essential to our success. That is why UCB’s ability to create value for patients now and into the future depends on the collaborative efforts of our 7 606 colleagues across the globe. Bringing differentiated solutions to all patients who need them also requires a genuine sense of accountability and leadership.

At UCB, diversity is defined as the collective richness of people’s unique backgrounds, life and cultural experiences and the diversity of thought this brings. Inclusion is respecting individual differences and capturing the advantages they provide. An inclusive culture at UCB involves the full and successful integration of everyone.

50 / 50 gender split

1 069 new colleagues joined us in 2019

1 024 colleagues left us in 2018

resulting in a 14% employee turnover



Curious to know more?

Find out how UCB is helping our employees live a fulfilled life in the 2019 annual integrated report.



Conducting business ethically and responsibly is fundamental to UCB’s core values. We have a strong culture of integrity, with policies and procedures in place to ensure the highest ethical standards are applied throughout the company’s value-chain.

Code of Conduct

UCB code of conduct provides a framework which helps us navigate through the challenging and evolving business and legal environments. 

The code of conduct, available in 14 languages, outlines general principles of business conduct and ethics that help guide every UCB colleague and UCB’s partners throughout the world when making decisions. It includes various topics, such as, conflict of interest, confidentiality, compliance, anti-bribery and anti-corruption, respectfulness, human rights and child labor policies, among others.

Stakeholders dialogue

Relations with patients

In addition to UCB’s own guidelines on patient group engagement and STAR (shared ambition, transparency, accountability, respect) principles, UCB follows the guidelines for interactions with patient organizations established by:

Relations with healthcare professionals

We aspire to maintain high standards of ethics and integrity in our interactions. We strongly believe that ensuring transparency in our financial relationships with healthcare professionals is essential to increase patients’ trust. Patients need to know that they can trust their doctors to recommend, prescribe and administer appropriate care and treatments based solely on clinical evidence and experience.

Relations with public authorities

UCB does not contribute to political candidates. In the U.S, UCB, Inc. has a voluntary political action committee (UCB Political Action Committee) which makes contributions to candidates and candidate committees; all contributions can be found in publicly available Federal Election Commission filings.

Board of Directors

  • 13 members
  • 4-year mandate
  • age limit: 70


Evelyn du Monceau, Chair of the Board


7 independent directors (54%)


6-year tenure average 

5 women (38%)

5 nationalities

61-year age average

Executive Committee

  • 9 members


Jean-Christophe Tellier, CEO


3 women (33%)


5 nationalities


57-year age average

8-year UCB tenure average